Clinical trial
Decitabine in Treating Patients With Advanced Solid Tumors
NCT00030615 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00030615 |
|---|---|
| Title | Decitabine in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Study Of The Toxicities, Biologic And Clinical Effects Of Daily 5 Aza 2'Deoxycytidine (DAC), NSC 127716 (IND 50733) For Four Weeks In Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Melanoma, Stage III Melanoma, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | decitabine, pharmacological study, laboratory biomarker analysis |
| Enrollment | 24 |
| Start date | Dec 1, 2001 |
| Primary completion | Sep 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: